Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

M

Methodist Health System

Status

Enrolling

Conditions

Liver Transplant Failure

Treatments

Behavioral: donor-derived cell free DNA in liver

Study type

Observational

Funder types

Other

Identifiers

NCT06225206
023.HEP.2023.D

Details and patient eligibility

About

Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.

Full description

dd-cfDNA is a non-invasive method to measure graft function stability in liver transplant patients. Liver biopsy is the standard to determine liver rejection and graft function, but no tests exist currently to be able to help guide the IS regimen in these patients. LFTs are not as specific to determine graft function hence testing dd-cfDNA levels can help guide the Immunosuppression (IS )medications dosing and help identify rejection early.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age: ≥18 years
  2. The patient underwent a liver transplant.
  3. The patient at least has one level of dd-cfDNA documented

Exclusion criteria

  • Patient not meeting the inclusion criteria will be excluded.

Trial contacts and locations

1

Loading...

Central trial contact

Bethany Brauer, MPH; Kavya Vinod Mankulangara, PharmD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems